AIP
EW icon

Arrowpoint Investment Partners’s Edwards Lifesciences EW Stock Holding History

Arrowpoint Investment Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,364
Closed -$1.4M – 110
2025
Q4 		$1.4M Buy
+16,364
New +$1.34M 0.21% 40

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Arrowpoint Investment Partners's EW Position: Q1 2026 in Review

Arrowpoint Investment Partners sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 16,364 shares — an estimated $1.4M sold.

Arrowpoint Investment Partners first reported a position in EW in Q4 2025 and held it in 1 quarter. The position peaked at $1.4M in Q4 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Arrowpoint Investment Partners reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
  • Arrowpoint Investment Partners sold 16,364 Edwards Lifesciences shares in Q1 2026, an estimated $1.4M.
  • Arrowpoint Investment Partners first reported a position in Edwards Lifesciences in Q4 2025 and held it in 1 quarter.
  • Arrowpoint Investment Partners's Edwards Lifesciences position peaked at $1.4M in Q4 2025.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.